Preparation, Characterization, and Stability of Liposome-Based Formulations of Mitoxantrone

10.1007/BF00685931

10.1016/S0099-5428(08)60221-X

10.1211/0022357011775451

Campbell M. J, 1995, Biotechniques, 18, 1027

Caride V. J, 1976, Journal of Nuclear Medicine, 17, 1067

10.1016/0003-9861(85)90498-9

10.2165/00003088-199018050-00003

Gabizon A. A, 1992, Cancer Research, 52, 891

Gokhale P. C, 2001, Anticancer Research, 21, 3313

Gregoriadis G, 1988, Liposomes as drug carriers—recent trends and progress, 3

10.1002/jps.2600670617

Lim H. J, 2000, Journal of Pharmacology and Experimental Therapeutics, 292, 337

10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U

Neidhart J. A, 1986, Journal of Clinical Oncology, 4, 672, 10.1200/JCO.1986.4.5.672

Novantrone, Serono, Inc. (2004). Physician's desk reference(58th ed.). Montvale, NJ: Tomson Healthcare Inc., 3128–3133

Oudard S, 1991, Cancer Chemotherapy and Pharmacology, 28, 259, 10.1007/BF00685532

10.1007/978-1-4615-3426-6_34

Poujol S, 1999, Anticancer Research, 19, 3327

10.1016/0024-3205(82)90098-4

Reska R, 1997, Journal of Pharmacology and Experimental Therapeutics, 280, 232

Thierry A. R, 1993, FASEB, 7, 572, 10.1096/fasebj.7.6.8097173